Comparative Pharmacology
Head-to-head clinical analysis: DIABINESE versus GLYNASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIABINESE versus GLYNASE.
DIABINESE vs GLYNASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Initial: 250 mg orally once daily, increase by 125-250 mg every 1-2 weeks as needed. Maintenance: 100-500 mg once daily. Maximum: 750 mg daily.
Initial dose 2.5-5 mg orally once daily with breakfast. Titrate by 2.5-5 mg weekly. Maximum dose 20 mg daily. Divided doses twice daily may be used for doses >10 mg.
None Documented
None Documented
Terminal elimination half-life 25–36 hours; in renal impairment, half-life prolonged significantly.
Terminal elimination half-life: 10-16 hours; clinical context: correlates with duration of glucose-lowering effect, prolonged in renal impairment.
Primarily renal (up to 80% unchanged); minor fecal (biliary) excretion (<10%).
Renal: approximately 50% as metabolites and unchanged drug; fecal/biliary: minor (less than 5% as unchanged drug).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic